Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals

globenewswire.com
NVS Novartis is mentioned as a major player in cell and gene therapy, with its drug Zolgensma generating significant sales. The article highlights the overall growth of the CGT market, which Novartis is part of. GILD Gilead Sciences, through its subsidiary Kite Pharma, is mentioned as a key player in the CGT market with its CAR-T therapy Yescarta generating substantial revenue. The article focuses on the overall market growth. BMY REGN While not explicitly mentioned, Regeneron is a major player in the biotech space and could be involved in cell and gene therapy. The article discusses the overall growth of the CGT market. CRSP CRISPR Therapeutics is mentioned as part of 'Other Gene Therapy Biotech,' indicating its involvement in the rapidly growing CGT sector. The article highlights the overall market expansion. NTLA Intellia Therapeutics is listed under 'Other Gene Therapy Biotech,' suggesting its role in the expanding cell and gene therapy market. The article focuses on the overall market growth and potential. EDIT Editas Medicine is included in the 'Other Gene Therapy Biotech' category, pointing to its participation in the burgeoning cell and gene therapy field. The article emphasizes the market's significant growth trajectory. BBIO Bluebird Bio is mentioned as a company in the cell and gene therapy space. The article highlights the overall market growth and the increasing number of FDA approvals in this sector. AZN AstraZeneca is listed with Algen Biotechnologies, indicating involvement in the cell and gene therapy sector. The article focuses on the overall market expansion and the positive outlook for CGT. SGMO Sangamo Therapeutics is mentioned as a company in the cell and gene therapy sector. The article highlights the overall market growth and the increasing number of FDA approvals in this field.

Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb leading the market through innovative treatments like CAR-T therapies and gene replacement therapies. Regulatory bodies like the FDA continue to approve new CGT products, reflecting a global push toward revolutionizing treatments for genetic disorders, blood cancers, and more.

1) Companies Data — Cell & Gene Therapy: Key Metrics

Novartis AG - Zolgensma (Gene Therapy for SMA)

Gilead Sciences / Kite Pharma - Yescarta (CAR-T Therapy)

Sangamo Therapeutics

Bristol Myers Squibb / 2seventy bio - Abecma (CAR-T Therapy)

Quell Therapeutics

Bharat Biotech / Nucelion Therapeutics (India)

AstraZeneca - Algen Biotechnologies

Bluebird Bio

Other Gene Therapy Biotech (CRISPR, Intellia, Editas)

2) Government / Regulatory Data on Cell & Gene Therapies

FDA - U.S. Regulatory Landscape

Global Approvals ASGCT Landscape

FDA Approval Trends (2024)

FDA Approval Breakdown (CAR-T Therapies)

Global Regulatory Data on Non-Modified Cell Therapies

3) Market Insights & Industry Overview

Cell and Gene Therapy Market Size, Shares and Statistical Data by 2035

The cell and gene therapy market size touched US$ 27.02 billion in 2025, with expectations of climbing to US$ 33.5 billion in 2026 and hitting US$ 232.22 billion by 2035, driven by a CAGR of 24% over the forecast period.

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5052

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest